FY2024 · ended Dec 31, 2024 · Revenue $536,357, +19.3% YoY · Filed Mar 28, 2025
Lipella Pharmaceuticals Inc. (LIPO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $536,357 and a net loss of $5.0 million. As of Sep 30, 2025 it held $1.9 million in cash and investments and $264,083 in total debt.
Revenue (TTM)
$389,783
-19.4% vs year-ago TTM
Net income (TTM)
$-5.33M
-25.0% vs year-ago TTM
Operating cash flow (TTM)
$-4.78M
-29.5% vs year-ago TTM
Free cash flow
$-3.16M
EPS (TTM)
$-1.76
+60.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.55M
-59.2% vs prior year
Net cash
$1.59M
as of Sep 30, 2025
Operating margin
-1387.9%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIPO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pittsburgh, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1347242
- Former names
- LIPELLA PHARMACEUTICALS INC (until Sep 11, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|
| Revenue | $536,357 | $449,617 | $184,156 |
| Operating income | -$5.1M | -$4.7M | -$2.6M |
| Net income | -$5.0M | -$4.6M | -$2.6M |
| Diluted EPS | -$4.79 | -$6.16 | -$0.64 |
| Operating cash flow | -$4.0M | -$3.2M | -$1.8M |
| Free cash flow | — | -$3.2M | — |
| Total assets | $2.7M | $3.6M | $6.0M |
| Total liabilities | $754,417 | $432,726 | $1.3M |
| Stockholders' equity | $1.9M | $3.1M | $4.7M |
| Cash and investments | $2.2M | $3.3M | $5.1M |
| Total debt | $47,605 | $136,594 | $154,520 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy
|
Jul 15, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Bankruptcy
|
Mar 31, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 4, 2026 | Feb 3, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 21, 2025 | Oct 20, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2025 | Oct 3, 2025 |
All 225 Lipella Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.